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SARS-CoV-2 that causes COVID-19 has emerged as a pandemic
with all continents now reporting cases, most of them community
acquired [1]. Many COVID-19 infections cause pneumonia and
some are fatal, predominantly among older adults [2]. Co-infection
with other viruses or bacteria, particularly those that similarly
cause inflammation of the respiratory tract would likely enhance
the risk for severe COVID-19 disease. Such disease enhancing co-
infections have been frequently reported for respiratory pathogens
[3–5], most notably so for the 1918 influenza pandemic [6,7]. Vac-
cinating older adults at elevated risk of severe COVID-19 disease
against vaccine preventable diseases may therefore not only help
to reduce the strain on the healthcare system from those diseases
during a pandemic, but also alleviate some of the potential COVID-
19 mortality due to co-infecting pathogens [8].
Vaccines that can prevent respiratory tract infections in adults
and particularly in older adults, either through direct protection
or indirectly through high coverage childhood immunisation pro-
grammes, include vaccines against seasonal influenza, Streptococ-
cus pneumoniae, measles, Bordetella pertussis and Haemophilus
influenzae type b (Hib). Measles, pertussis and Hib vaccines are
already included in almost all routine infant immunisation pro-grammes globally and have largely eliminated the targeted patho-
gens as a risk to the older adult population through indirect
protection [9]. Hence, they have limited scope for use in older
adults in order to limit COVID-19 morbidity and mortality. Pneu-
mococcal conjugate vaccine (PCV), either 10- or 13-valent, is used
in three-quarters of routine infant immunisation programs glob-
ally; in countries that use PCV, the burden of adult pneumococcal
disease due to PCV serotypes has also substantially decreased [10].
These considerations mean there is a relatively small preventable
disease burden in countries routinely using PCV in children. As vac-
cine costs are relatively high and there is no current World Health
Organisation recommendation regarding PCV use in adults, PCVs
are not considered further here. Two vaccines that target a large
burden of the remaining respiratory disease in older adults are sea-
sonal influenza vaccines and 23-valent pneumococcal polysaccha-
ride vaccine (PPV23). These vaccines are only included in routine
adult immunisation in some countries and even there with only
moderate coverage [11]. We conducted a non-systematic review
of the published, pre-print and grey literature to evaluate whether
vaccination of older adults with seasonal influenza vaccine or
PPV23 could help reduce COVID-19 mortality.
2. Seasonal influenza vaccines
The World Health Organization recommends seasonal influenza
vaccine use for pregnant women as well as older adults (>65yrs),
Table 1
Estimating COVID-19 death attributable to influenza and pneumococcal coinfection.
Parameter description Minimum value Maximum value Reference
Seasonal influenza vaccine efficacy 20% 60% [17,18]
COVID-19 deaths attributable to influenza coinfection (assuming it is
similar to COVID-19 cases attributable to influenza co-infection)
0% 60% [19–24]y
Preventable COVID-19 deaths due to influenza co-infection 0 * 0.2 = 0% 0.6 * 0.6 = 36%
PPV23 vaccine efficacy 20% 60% [28–30]
PPV23 preventable serotypes in older adults 48% 66% [26]
COVID-19 deaths attributable to pneumococcal co-infection
(assuming it is similar to influenza A (H1N1) deaths attributable to pneumococcal co-infection)
0% 25% [6]
Preventable COVID-19 deaths due to pneumococcal co-infection 0.2 * 0.48 * 0 = 0% 0.6 * 0.66 * 0.25 = 10%
y In five studies, co-infection occurred in 41/68, 0/20, 11/127, 0/99 and 5/115 cases.
 In seven studies, co-infection occurred in 0/100, 2/182, 2/45, 13/585, 20/199, 2/585 and 5/21 cases.
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(particularly HIV) [12]. In 2014, 45% of countries globally had
established a seasonal influenza vaccine programme that targets
older adults, hardly any of them are in low or middle income coun-
tries [13].
Seasonal influenza as a risk factor for COVID-19 could be an
important consideration in tropical climates and the southern
hemisphere, and potentially during future waves of COVID-19 in
the northern hemisphere [14–16]. Inactivated influenza vaccine
effectiveness varies markedly by season from about 20% in seasons
with a poor match to the circulating strains to up to 60% for closer
matched seasons [17,18]. Hence, influenza vaccination could pre-
vent 20% to 60% of influenza infections and thereby potentially a
similar percentage of influenza-attributable COVID-19 morbidity
and mortality (Table 1).
A number of studies to date have tried to assess the percentage
of influenza-attributable COVID-19 morbidity and mortality. Some
reported the occurrence of co-infection of COVID-19 inpatients
with influenza viruses, although the proportion of co-infections
varies by study, from no influenza coinfection identified to more
than 60% of PCR positive COVID-19 patients being currently or hav-
ing been recently infected with influenza [19–25]. Whether this
co-occurrence is co-incidental, or indeed influenza contributes to
the clinical severity of COVID-19 presentation is not yet clear.
However, to date there is no evidence that would suggest clinical
manifestations in COVID-19 patients with influenza co-infection
differ from those without co-infection [19].3. Pneumococcal polysaccharide vaccine
PPV23 targets 23 of the over 90 serotypes that are responsible
for most adult pneumococcal disease. In countries with an infant
PCV program, about 48–66% of invasive pneumococcal disease
(IPD) in older adults is caused by serotypes that PPV23 is effective
against [26]; in countries without an infant PCV programme this
percentage is likely about 20% higher (details see Appendix).
PPV23 is recommended for routine use in older adults in most
high-income countries, but rarely in low and middle-income coun-
tries [27]. It provides short-term protection against IPD caused by
vaccine serotypes in healthy older adults with a pooled efficacy
across targeted serotypes of about 60% [28–30]. However, PPV230s
effectiveness is much lower among high risk groups including the
immunocompromised [31–33], who may be at particular risk for
severe COVID-19. Consequently, PPV23 use in older adults could
prevent up to 33–40% of pneumococcal disease and thereby poten-
tially pneumococcal-attributable COVID-19 morbidity and mortal-
ity (Table 1).
The extent of pneumococcal-attributable COVID-19 morbidity
and mortality is largely unknown. Pneumococci have been identi-
fied as a major source for often fatal secondary bacterial infectionsduring pandemic and seasonal influenza infections. Estimates for
the proportion of pneumococcal co-infections among pandemic
influenza deaths range from about 7% during the 2009 H1N1 pan-
demic to more than 50% during the 1918 pandemic [6,34–37]. Few
studies so far have tried to identify bacterial co-infections among
COVID-19 cases, and those that did found very few bacteria and
only a limited number of cases with pneumococci [23,38,39]. This
may be due to the empirical treatment with antimicrobials for the
majority of severely ill suspected COVID-19 patients, or because
bacterial infection plays little role in the severity of COVID-19 dis-
ease [23,40]. However, elevated procalcitonin levels, a sensitive but
not very specific biomarker for bacterial infections, have been
reported in 13% of severe and 25% of fatal COVID-19 infections,
but largely absent in COVID-19 infected persons with less severe
outcomes, which may suggest some role for bacterial coinfection
[41,42].
4. COVID-19 associated risk of attending clinics to receive PPV23
or influenza vaccination
Attending a vaccination clinic during the COVID-19 pandemic
will likely come with an excess risk of SARS-CoV-2 infection. This
risk may be small, particularly if physical contact reducing
interventions are implemented. To illustrate the potential magni-
tude of such excess risk, we assume a reasonably high COVID-19
burden scenario: contact reducing interventions can be imple-
mented and upheld to substantially slow COVID-19 spread but
not contain it, so that after 6 months and in the absence of a
COVID-19 vaccine herd immunity will end the outbreak [43].
Assuming a basic secondary attack rate of R0 = 2.5 and that con-
tact-reducing interventions spread the COVID-19 infection risk
equally across that 6-month time period, the increase in risk for
COVID-19 acquisition attributable to the vaccination clinic visit
would be roughly 0.3–1.3%, depending on the effectiveness of
transmission-reducing measures during the vaccination visits
(details see Appendix) [44]. This implies, that if either seasonal
influenza vaccine or PPV23 reduces COVID-19 morbidity and mor-
tality by a similar amount or more, their benefit on COVID-19 alone
would outweigh the risk associated with the vaccination visit in
this scenario, while also preventing morbidity from influenza and
pneumococcal disease.
5. Conclusion
Both seasonal influenza vaccine and PPV23 can prevent a sub-
stantial burden of targeted disease and mortality among older
adults and adults at-risk. Despite a potential collateral reduction
in influenza and pneumococcal circulation due to contact reducing
interventions, in countries where the COVID-19 pandemic coin-
cides with the season of high risk for pneumococcal and/or influ-
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fits: minimising the number of pneumococcal and influenza hospi-
tal admissions reduces the resources needed to care for non-
COVID-19 patients and minimises the risk of health-care acquired
COVID-19 infection. For influenza, the similarity of symptoms with
COVID-19 cases also suggests that vaccination will increase the
specificity of syndromic COVID-19 surveillance. Similarly, main-
taining high vaccine coverage of existing PCV and live attenuated
influenza vaccine programmes in children reduces the associated
disease burden in older adults through herd effects, and will fur-
ther enhance benefits for limiting COVID-19 risks.
The magnitude of COVID-19 morbidity and mortality prevented
by influenza vaccine and PPV23 is probably relatively small,
although at present we cannot exclude the possibility of either pre-
venting a considerable amount of COVID-19 related mortality
(Table 1). This uncertainty highlights the importance for detailed
monitoring and additional studies where possible, in both high
and low income settings. The proportion of vaccine preventable
COVID-19 morbidity and mortality could be assessed, for example,
by post mortem examinations or test-negative case-control studies
[45].
In summary, where already in routine use among older adults
and/or adults at-risk, maintaining both seasonal influenza and
PPV23 at high coverage have the potential to not only reduce the
burden of the targeted diseases but also prevent a proportion of
COVID-19 morbidity and mortality, if they can be delivered while
minimising the risk for SARS-CoV-2 transmission. However, for
countries who previously decided that seasonal influenza vaccine
or PPV23 programmes for older adults are not a priority, there is
currently little evidence to encourage implementation of either
during the COVID-19 pandemic solely for the purpose of reducing
COVID-19 mortality.Funding
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Proportion of PPV23 serotypes among older adults
The PSERENADE project aims to understand the impact of
PCV10/13 on invasive pneumococcal disease (IPD) incidence and
serotype distribution using IPD data contributed by surveillance
sites across the world. In settings with mature PCV10/13 infant
immunization programmes, the estimated proportion of IPD in
older adults (65 years of age) attributable to PPV23 serotypes is
67–79% for countries using PCV10 in infants and 68–71% for coun-
tries using PCV13. Excluding ST3 (PPV23-minus-ST3), these pro-
portions drop to 48–66% and 51–57% respectively. Because
effectiveness against ST3 has not been observed in all countries,
the proportion of IPD in older adults attributable to PPV23-
minus-ST3 is used here as a more conservative estimate of pre-
ventable disease. In the time period prior to PCV use in children,
the estimated proportion of IPD in older adults attributable to
PPV23-minus-ST3 serotypes was about 20% higher; this can be a
proxy for countries without an infant PCV programme. However,
most of the data included comes from high-income countries and
may not be entirely representative of the serotype distribution in
countries without a PCV programme, which are mostly low and
middle income.Risk of SARS-CoV-2 infection during a vaccination clinic visit
Assume that contact reducing interventions spread the risk of
COVID-19 out roughly equally over a 6 month period. This scenario
is in line with model predictions for SARS-CoV-2 spread in the
presence of a 50% reduction in contacts for the duration of
6 months. Assuming an R0 of 2.5 and a duration of infectiousness
of 1 week means that about 60% of the population will have been
infected at the end of the pandemic and that at any one time about
2% of the population is infectious. Further, assume that an adult
attends a vaccination clinic and makes a total of 2–10 contacts
(hereby 2 may reflect a scenario of effective measures to avoid con-
tacts) related to that visit and that the probability of infection per
potentially infectious contact is about 10% (R0 attributed over the
number of contacts during the infectious period e.g. 2.5 transmis-
sions during the two days before symptom onset and self-isolation,
with 12 contacts per day before isolation). Then the probability
for SARS-CoV-2 infection during that vaccine clinic visit is
P = 1 - (1–10%)#contats * 2% = 0.4 to 2%. Hence, the excess absolute
risk for SARS-CoV-2 infection over the pandemic baseline risk is
D. Thindwa et al. / Vaccine 38 (2020) 5398–5401 5401P*(1–60%) and corresponds to a relative risk increase over the pan-
demic baseline risk of 0.3 to 1.3%.References
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